Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioPharma is positioned favorably because its future growth is centered on EXXUA, which was commercially launched in Q4 2025 and has already seen an encouraging early launch, including completed sales force training in mid-January 2026. The drug’s profile is also compelling, as it effectively relieves depressive symptoms without labeling warnings or adverse reactions for sexual dysfunction or weight gain versus placebo, supporting differentiation in a large CNS market. Fundamentally, the setup appears attractive because the stock trades well below estimates of future sales while conservative forecasts still imply FY27 revenues of $68 million to $70 million and either a $3 million loss or $5 million net income, with meaningful upside if EXXUA gains traction.

Aytu BioPharma is facing a fundamentally weak near-term setup, as fiscal Q3 FY26 revenue fell 33% year over year to $12.4 million while pro forma EPS of $(0.43) showed continued losses and no Q3 guidance was provided. Although EXXUA addresses a large MDD market, commercialization remains challenging and the company still faces material risks around safety and efficacy, regulatory approvals, reimbursement, and competition. With balance sheet and liquidity concerns also cited, its dependence on the ADHD Portfolio and broader biotech sentiment leaves the stock vulnerable despite long-term opportunity.